1. Introduction {#s0005}
===============

Metabolic syndrome (MetS) embraces different metabolic defects. These comprise central fatness, hypertension, insulin resistance and dyslipidemia. The syndrome poses a significant risk for cardiovascular disease (CVD) ([@b0200], [@b0240]). Unfortunately, the worldwide incidence of MetS is riskily high ([@b0015], [@b0025]). Pathogenesis of MetS encompasses genetic and epigenetic factors ([@b0250], [@b0140]) that are linked to initiation of several inflammation pathways and eventually lead to CVD. Molecular mechanisms that mediate MetS have been reviewed ([@b0030]). However, peroxisome proliferator-activated receptors-gamma (PPARγ) regulators and adenosine monophosphate-activated protein kinase (AMPK) activators have been proposed for the treatment and management of MetS ([@b0255], [@b0230]). Pharmacological management of MetS includes statins, ACE inhibitors, metformin, canagliflozin, exenatide and drugs belonging to their classess ([@b0195]). However, the increasingly rate of incidence MetS and obesity indicates that effectiveness of the available medications is unsatisfactory and necessitates the search of new therapies. In this regard, natural products represent a safe and effective alternative.

*Crocus sativus* L-- known as Saffron -- has been exploited as a coloring agent and food spice culinary purposes. In addition, the plant is widely used in traditional remedy as anti-spasmodic, sedative, stomachic, carminative, expectorant, and aphrodisiac ([@b0040]). Crocin is a major apo-carotenoid of saffron ([@b0050]). Experimentally, crocin has been shown to possess antinociceptive ([@b0060]), learning and memory enhancing ([@b0150]), neuroprotective ([@b0180]), nephroprotective ([@b0125]), hepatoprotective ([@b0130]), cardioprotective ([@b0080]) and antiosteoporotic ([@b0020]) activities. Further, crocin has been shown to combat elements of MetS in different animal models. It significantly reduced weight gain and alleviated experimentally obesity in rats induced by high fat content in animal diet ([@b0020]). In experimentally-induced diabetes, crocin amended insulin resistance and dyslipidemia ([@b0245]). Also, crocin prevented hypertension induced by angiotensin II in rats ([@b0220]). The objective of this work was to address whether or not crocin could prevent experimentally-induced MetS in rats as well as the probable causal mechanisms.

2. Materials and methods {#s0010}
========================

2.1. Chemicals {#s0015}
--------------

Crocin, fructose and sodium chloride were bought from Merck, Taufkirchen, Germany. Other used chemicals were highly pure (\>98%).

2.2. Animals and animal treatment {#s0020}
---------------------------------

Twenty-four Wistar rats (male gender, weight range 140--170 g) were got from the local vivarium (College of Pharmacy, University of King Abdulaziz, Saudi Arabia). Daily, rats were retained at fixed temperature of 23 ± 2 °C and 12-h dark-light succession. Animal handling in the current study was endorsed in advance by Biomedical Ethics Unit at the College of Medicine, University of King Abdulaziz (Ref. \# 329--16). Animals were grouped into 4 sets (6 each). The control (group 1) received regular drinking water and standard food pellets. Second third and fourth groups were exposed to investigational MetS. Induction of MetS was achieved by giving the animals food pellets containing 3% NaCl; and drinking water enriched with 10% fructose. Exposure to high salt food pellets and high fructose drinking water continued for 12 weeks ([@b0005]). The first and second group were orally administered saline on a daily basis, while groups 3 & 4 were gavaged with crocin at two daily doses (5 or 10 mg/kg); respectively. Doses of crocin are supported by a preliminary experiment and in harmony with previous animal studies ([@b0290], [@b0020]). Crocin treatments were repeated for 5 days per week during the 12-week experimental period. Animals weights were recorded every 3 weeks. Blood pressure was assessed at the last day of week 12. This was followed by collecting blood samples from tail veins for determining glucose levels. At the first day of week 13, rats were allowed to inhale ether in a closed chamber for anesthesia. Then, samples of blood were collected from the plexus located retro-orbitally and allowed to clot. This was followed by centrifugation to get sera that were stored at −80 °C for subsequent analyses. Abdomens were quickly opened and visceral fat from each animal was collected and weighed. Finally, animals were sacrificed by decapitation.

2.3. Blood pressure measurement {#s0025}
-------------------------------

Rats were restrained, kept in a warming chamber and subjected to conditioning for 10--20 min daily for 3 consecutive days. Then, blood pressure (BP) was determined as previously described ([@b0055]) in conscious, moderately restrained rats using the tail cuff method. Measurements were executed between 8:00 and 11:00 AM. Routinely, inflation--deflation cycles were repeated 10 times, separated by 5 and 10 min of stabilization in at 35 °C in a warm chamber. Blood pressure was calculated as the average of 6 determinations within a narrow range of 6--10 mmHg. Mean arterial pressure (MAP) was computed as follows:$$MAP = Diastolic\mspace{900mu} BP + \frac{(Systolic\mspace{900mu} BP - Diastolic\mspace{900mu} BP)}{3}$$

2.4. Blood analysis {#s0030}
-------------------

Glucose levels (Fasting and postprandial) in tail vein blood were measured by an appropriate glucometer (ACCU-CHEK obtained from Roche, Mannheim, Germany). Levels of blood insulin in fasted animals were assessed using rat insulin ELISA Kit (Cayman, Ann Arbor, MI, USA) and expressed as µU/L. HOMA-IR was computed according to [@b0100]$$HOMA - IR = Fasting\mspace{900mu} glucose\mspace{900mu}{(mg/dL)} \times \frac{Fasting\mspace{900mu} insulin\mspace{900mu}(mU/L))}{405}$$

Total cholesterol (TC), triglycerides (TG) and high density lipoprotein cholesterol (HDL-C) were determined using commercially available kits obtained from Biodiagnostics® (Giza, Egypt). Additionally, cholesterol of the type very low density lipoprotein was computed as VLDL-C = TG/5. Low density lipoprotein cholesterol known as LDL-C was computed as follows: LDL = TC − (VLDL + HDL) ([@b0085]). Serum PPARγ was determined by means of ELISA Kit (Bioassay Technology Laboratory Company, Shanghai, China). Similarly, serum level of PAMPK was assessed by a commercially available ELISA kit (MyBioSource, San Diego, USA). Finally, serum content of IL-6 and TNF-α was evaluated by ELISA kits (Jiancheng, Nanjing, China) according to the producer\'s instructions.

2.5. Statistical analyses {#s0035}
-------------------------

Means ± SD were used to present collected data. Significant differences between means were tested using one-way ANOVA. Bonferroni was used as a post *hoc* test (GarphPad Instat software, version 3.1, San Diego, CA, USA). The level of 0.05 was used as a cut-off value of significance (*p \< 0.05).*

3. Results {#s0040}
==========

3.1. Effect of crocin on weight gain and adiposity index {#s0045}
--------------------------------------------------------

Overweight is one of the major determinants of MetS. Therefore, body weight and fatty changes were assessed in the current animal model of MetS. As shown in **(**[Fig. 1](#f0005){ref-type="fig"}**)**, animals suffering from MetS started to show a significant increase in their body weights at the sixth week after induction, compared to the control rats. Treatment with crocin (5 mg/kg) failed to demonstrate any significant decrease in body weight from MetS group except at the last week of experiment (week 12). However, crocin (10 mg/kg) was more efficient and significantly reduced the body weight from MetS group, starting from the ninth week of model induction. These findings were further confirmed by calculating weight gain percentage as indicated in [Table 1](#t0005){ref-type="table"}. Rats with MetS showed a significant rise in their weight gain by 53%, in comparison to the control group. Unfortunately, crocin (5 mg/kg) caused insignificant reduction of weight gain compared to MetS group. Yet, crocin (10 mg/kg) significantly reduced weight gain by about 23% as compared to MetS rats. Other markers of fatty changes like visceral fat weight and adiposity index have added to the obtained outcomes, as specified in [Table 1](#t0005){ref-type="table"}. Weight of visceral fat was increased significantly in MetS group by about 80% in comparison to control animals. Crocin at both lower and higher doses successfully induced a significant decrease of visceral fat as compared to MetS group, in a dose-related manner. Moreover, crocin higher dose (10 mg/kg) was more effective than the lower dose and almost restored visceral fat to the control value. Similar pattern of activity has been shown with the adiposity index, in which MetS caused about 45% increase, compared to the control animals, while crocin showed a dose-related decrease of adiposity index, in comparison to MetS animals.Fig. 1Influence of crocin on weight gain in metabolic syndrome (MetS)-induced rats. Data are displayed as Mean ± S.D. Statistical analysis was carried out using one-way ANOVA followed by Tukey's post-hoc test. (a) Significantly different from control at p \< 0.05. (b) Significantly different from MetS group at p \< 0.05.Table 1Influence of crocin on weight gain and adiposity index in metabolic syndrome (MetS) rats.Initial body weight (g)Final body weight (g)Weight gain (%)Visceral fat (g)Adiposity indexControl153.3 ± 7.8264 ± 10.072.4 ± 6.010.7 ± 0.74.06 ± 0.3MetS151.8 ± 6.7325.6[a](#tblfn1){ref-type="table-fn"} ± 15.1110.8[a](#tblfn1){ref-type="table-fn"} ± 12.719.3[a](#tblfn1){ref-type="table-fn"} ± 0.85.9[a](#tblfn1){ref-type="table-fn"} ± 0.3MetS + Crocin 5 mg/kg149.5 ± 12.1288.0[a](#tblfn1){ref-type="table-fn"}, [b](#tblfn2){ref-type="table-fn"} ± 17.093.7 ± 18.913.8[a](#tblfn1){ref-type="table-fn"}, [b](#tblfn2){ref-type="table-fn"} ± 1.04.8[a](#tblfn1){ref-type="table-fn"}, [b](#tblfn2){ref-type="table-fn"} ± 0.3MetS + Crocin 10 mg/kg148.7 ± 5.5275.0[b](#tblfn2){ref-type="table-fn"} ± 11.285.4[b](#tblfn2){ref-type="table-fn"} ± 13.111.9[b](#tblfn2){ref-type="table-fn"}, [c](#tblfn3){ref-type="table-fn"} ± 0.84.4[b](#tblfn2){ref-type="table-fn"} ± 0.4[^1][^2][^3][^4][^5]

3.2. Influence of crocin on FBG, insulin concentrations, HOMA-IR and OGTT {#s0050}
-------------------------------------------------------------------------

Because overweight is usually connected to glucose intolerance in MetS, FBG and serum insulin levels were assessed. This was followed by calculation of HOMA-IR as a marker of insulin resistance, as indicated in [Table 2](#t0010){ref-type="table"}. Levels of both FBG and of serum insulin were significantly raised in MetS rats by about 70% and 36% respectively, compared to the corresponding control groups. Animals given crocin (5 mg/kg) showed significant decrease of both markers by about 15% and 23% respectively, compared to the corresponding MetS groups. Moreover, crocin (10 mg/kg) markedly improved glucose tolerance, being able to ameliorate MetS-induced elevations of fasting blood glucose and serum insulin, so that no significant differences were detected compared to the corresponding controls. These finding were reflected on insulin resistance measured as HOMA-IR that was increased by more than 2-folds in MetS group, compared to control animals. Meanwhile, crocin (5 and 10 mg/kg) was capable of decreasing HOMA-IR values by about 34% and 51% respectively, compared to MetS group. Oral glucose tolerance test further confirmed the previous results as shown in [Fig. 2](#f0010){ref-type="fig"}**.** Rats with MetS showed glucose intolerance manifested by significantly high blood glucose levels over 120 min, compared to the control group. Again, crocin improved glucose tolerance in a dose-related with the ability of crocin (10 mg/kg) dose to significantly reduce blood glucose level at all-time intervals, compared to both MetS group and the other one given crocin at the lower dose (5 mg/kg).Table 2Influence of crocin on FBG and insulin concentrations, and HOMA-IR in metabolic syndrome (MetS)-induced rats.FBG (mg/dL)Fasting serum insulin (μU/L)HOMA-IRControl83.82 ± 6.3512.30 ± 1.302.54 ± 0.26MetS142.87[a](#tblfn4){ref-type="table-fn"} ± 10.6716.74[a](#tblfn4){ref-type="table-fn"} ± 2.025.92[a](#tblfn4){ref-type="table-fn"} ± 0.94MetS + Crocin (5 mg/kg)122.00[a](#tblfn4){ref-type="table-fn"}, [b](#tblfn5){ref-type="table-fn"} ± 12.3312.90[b](#tblfn5){ref-type="table-fn"} ± 1.403.90[a](#tblfn4){ref-type="table-fn"}, [b](#tblfn5){ref-type="table-fn"} ± 0.68MetS + Crocin (10 mg/kg)94.00[b](#tblfn5){ref-type="table-fn"}, [c](#tblfn6){ref-type="table-fn"} ± 11.7712.40[b](#tblfn5){ref-type="table-fn"} ± 1.502.90[b](#tblfn5){ref-type="table-fn"} ± 0.65[^6][^7][^8][^9][^10]Fig. 2Influence of crocin on OGTT in metabolic syndrome (MetS)-induced rats. Data are displayed as Mean ± S.D. Statistical analysis was carried out using one-way ANOVA followed by Tukey's post-hoc test. (a) Significantly different from control at p \< 0.05. (b) Significantly different from MetS group at p \< 0.05. (c) Significantly different from crocin (5 mg/kg) at p \< 0.05.

3.3. Influence of crocin on metabolic syndrome (MetS)-induced dyslipidemia {#s0055}
--------------------------------------------------------------------------

It is worthy noted that hyperlipidemia and hypertension are common characteristics of MetS, therefore, lipid profile and blood pressure changes were evaluated in the current animal model. As indicated in [Table 3](#t0015){ref-type="table"}, MetS induced hyperlipidemia manifested by significant elevations of TG, LDL-C and TC accompanied with a fall in HDL-C, in comparison to corresponding control groups. Crocin at 5 mg/kg significantly reduced only TG and LDL-C, compared to corresponding MetS groups. However, crocin (10 mg/kg) could significantly reduce TC in addition to TG and LDL-C, compared to their corresponding MetS groups. Both doses of crocin caused non-significant increases of HDL-C level compared to MetS group.Table 3Effect of crocin on metabolic syndrome (MetS)-induced dyslipidemia in rats.TG (mg/dL)HDL-C (mg/dL)LDL-C (mg/dL)TC (mg/dL)Control91.20 ± 8.121.2 ± 3.823.5 ± 3.383.41 ± 5.3MetS223.2 [a](#tblfn7){ref-type="table-fn"} ± 14.114.6 [a](#tblfn7){ref-type="table-fn"} ± 2.535.9 [a](#tblfn7){ref-type="table-fn"} ± 2.93140.4 [a](#tblfn7){ref-type="table-fn"} ± 7.8MetS + Crocin (5 mg/kg)173.9[a](#tblfn7){ref-type="table-fn"}, [b](#tblfn8){ref-type="table-fn"} ± 16.316.8 ± 2.327.7[b](#tblfn8){ref-type="table-fn"} ± 3.4128.9[a](#tblfn7){ref-type="table-fn"} ± 11.5MetS + Crocin (10 mg/kg)133.7[a](#tblfn7){ref-type="table-fn"}, [b](#tblfn8){ref-type="table-fn"}, [c](#tblfn9){ref-type="table-fn"} ± 15.818.8 ± 2.726.4[b](#tblfn8){ref-type="table-fn"} ± 2.3125.0[a](#tblfn7){ref-type="table-fn"}, [b](#tblfn8){ref-type="table-fn"} ± 5.8[^11][^12][^13][^14][^15]

3.4. Influence of crocin on blood pressure {#s0060}
------------------------------------------

Regarding blood pressure changes, MetS induced significant increases in systolic, diastolic and mean arterial pressures by about 28%, 25% and 26% respectively, compared to the corresponding control groups, as shown in [Table 4](#t0020){ref-type="table"}. Crocin at the lower dose (5 mg/kg) could not reduce systolic pressure, compared to MetS group. However, crocin (10 mg/kg) could obviously ameliorate MetS-induced hypertension, being able to normalize systolic, diastolic and mean arterial pressures as manifested by absence of any statistical differences from their corresponding controls.Table 4Influence of Crocin on blood pressure of metabolic syndrome (MetS)-induced rats.Systolic BP (mmHg)Diastolic BP (mmHg)Mean arterial BP (mmHg)Control108.1 ± 7.675.3 ± 5.586.2 ± 5.5MetS138.3[a](#tblfn10){ref-type="table-fn"} ± 10.193.9[a](#tblfn10){ref-type="table-fn"} ± 6.0108.7[a](#tblfn10){ref-type="table-fn"} ± 6.7MetS + Crocin (5 mg/kg)129.4[a](#tblfn10){ref-type="table-fn"} ± 5.679.9[b](#tblfn11){ref-type="table-fn"} ± 6.596.4[a, b](#tblfn10){ref-type="table-fn"} ± 4.5MetS + Crocin (10 mg/kg)119.7[b](#tblfn11){ref-type="table-fn"} ± 10.077.1[b](#tblfn11){ref-type="table-fn"} ± 5.691.3[b](#tblfn11){ref-type="table-fn"} ± 6.2[^16][^17][^18][^19]

3.5. Influence of crocin on serum levels of PPARγ, pAMPK, IL-6 and TNF-α {#s0065}
------------------------------------------------------------------------

In order to investigate how crocin improved experimentally-induced MetS in rats, serum levels of PPARγ, phosphor-AMPK, IL-6 and TNF-α were quantified. As shown in [Fig. 3](#f0015){ref-type="fig"}**A,** MetS-induced a significant drop of PPARγ level, when compared with control values. Crocin at both doses improved PPARγ level when compared to values of MetS animals with no significant difference was detected from the control group. A similar pattern was observed with phosphor-AMPK that represents the active form of AMPK enzyme, as shown in [Fig. 3](#f0015){ref-type="fig"}B. Though, the effect of crocin was dose-related, where only (10 mg/kg) dose could restore phospho-AMPK level to the control value. Regarding the inflammatory biomarkers IL-6 and TNF-α, they had the same pattern as demonstrated in [Fig. 3](#f0015){ref-type="fig"}C and D. Animals suffering from MetS had significant increases of both markers, in comparison to the corresponding control groups. Contrariwise, crocin at doses of 5 and 10 mg/kg significantly ameliorated such changes, being able to reduce IL-6 and TNF-α to normal values with no significant differences from the corresponding controls.Fig 3Influence of Crocin on serum levels of PPARγ, pAMPK, IL-6 and TNF-α in metabolic syndrome (MetS) rats. Data are displayed as Mean ± S.D. Statistical analysis was carried out using one-way ANOVA followed by Tukey's post-hoc test. (a) Significantly different from control at p \< 0.05. (b) Significantly different from MetS group at p \< 0.05.

4. Discussion {#s0070}
=============

The current study aimed at exploring the influence of crocin on the progress of MetS induced by high fructose-drinking water and high salt-food in rats. The used model for induction of MetS is a standardized experimental approach and it results in development of all signs of the disease as reviewed by [@b0185]. Administration of crocin (5 and 10 mg/kg) significantly inhibited weight gain. This is in accordance with previous investigations highlighting the anti-obesity properties in animals exposed to 10-week-long high-fat diet (HFD) ([@b0105]). Further, crocin has been reported to protect against complications of obesity as fatty liver in obese rats ([@b0175]). In addition, our data indicated that crocin significantly prevented the rise in adopsity index. In humans, crocin improved appetite accumulation of central obesity in patients with coronary artery disease ([@b0010]). Anti-obesity activity of crocin was proposed to encompass AMPK-mediated inhibition of adipocyte differentiation in addition to enhancement of lipolysis ([@b0095]).

Our results indicate that crocin protected against MetS-induced hyperglycemia. This was confirmed by controlled rise in blood glucose levels in OGGT. The potential of crocin to combat hyperglycemia in experimentally-induced diabetes has been previously described ([@b0190]). Further, crocin has been shown to protect against several diabetic complications experimentally. These include nephropathy ([@b0280]), compromised memory and learning ([@b0260]), elevated HbA1c & microalbuminuria ([@b0245]), peripheral neuropathy ([@b0075]) and impaired spermatogenesis ([@b0205]). Additionally, crocin treatment has been reported to inhibit apoptotic changes in pancreatic β-islets and pancreatic atrophy in experimental diabetes in rats ([@b0035], [@b0215]). Our data also illustrated that crocin treatment significantly prevented against hyperinsulinemia and insulin resistance as indicated by ameliorating the rise in HOMA-IR. This observation is in line with earlier studies showing crocin's ability to improve insulin resistance in diabetic rats ([@b0245]). Also, crocin improved HOMA-IR in type 2 diabetes in rats induced by streptozotocin/high fat diet ([@b0090]).

Induction of MetS in rats was associated with dyslipidemia. However, crocin significantly prevented the rise in serum TG, LDL-C & TC and the decline in HDL-C. This finding gains support by an earlier reports indicating the ability of crocin to prevent the rise of the same parameters in diabetic animals ([@b0245]). In rats, crocin ameliorated the rise in levels of hyperlipidemic markers via inhibition of lipase enzyme ([@b0235]). Also, crocin ameliorated diazinon-induced hyperlipemia in rats. The mechanism was suggested to involve modulation of ERK pathway and increase of LDL receptor upragulation ([@b0145]). Complications of dyslipidemia as atherosclerosis were prevented by crocin in rats kept on high cholesterol diet for 2 months ([@b0270]).

Our data indicated that crocin significantly protected against MetS-induced rise in PB. Experimentally, crocin was previously shown to prevent hypertension induced by deoxycorticosterone acetate in rats ([@b0115], [@b0120]). It has been suggested that crocin\'s antihypertensive activities involve inhibition of renin-angiotensin system (RAS). This is supported by the ability of crocin to prevent acute hypertension that was induced by angiotensin II in sedated rats ([@b0220]). Also, protection by crocin against endothelial injury ([@b0275]) may be included. Additionally, modulation of intracellecular Ca^2+^ levels in vascular smooth muscles cannot be excluded. Crocin has been shown to impede both Ca^2+^ influx from extracellular compartments along with the release of intracellular Ca^2+^ in cells isolated from bovine aortic smooth muscles ([@b0110]).

The obtained results in this study clearly indicate crocin capability to protect against MetS. This gains support by a report suggesting saffron and its constituents are effective in attenuating MetS complications including obesity, hyperglycemia, dyslipidemia and hypertension ([@b0135], [@b0225]). In humans, saffron prevented MetS in psychotic patients on olanzapine treatment ([@b0070]). The possible underlying mechanisms of the observed activities of crocin against MetS were explored. Our data indicate that crocin significantly enhanced serum PPARγ levels. Peroxisome proliferator-activated receptors (PPARs) possess significant impact on metabolic regulation of blood lipids, blood glucose, and abdominal adiposity ([@b0045]). In general, PPAR agonists have been suggested to combat MetS ([@b0165]). In particular, PPARγ activators have proven potent in combating hypertension and MetS ([@b0255]). These reports lend support to our findings. Further, the role of AMPK in fighting diabetes and MetS has been reported ([@b0285]). Also, AMPK activators are effective in preventing insulin resistance and MetS ([@b0210]). These reports give support to our observations of enhancement blood AMPK levels by crocin. Due to their safety profile, natural AMPK activators have been recommended for preventing MetS ([@b0230]). In this regard, crocin has been previously reported to activate AMPK signaling leading to enhanced β-oxidation of fatty acids and inhibited lipogenesis in mice ([@b0155]). Also, our results highlighted anti-inflammatory activities of crocin as indicated by preventing the elevation of blood IL-6 and TNF-α. These data are consistent with the observed activation of PPARγ and AMPK ([@b0170], [@b0160]). Inflammation has been shown to link obesity, diabetes and MetS ([@b0065]). Therefore, targeting inflammation has been give attention to fight MetS ([@b0265]). In conclusion, crocin protects against experimentally-induced MetS. This can be attributed, at least partly, to activation PPARγ and AMPK as well as inhibiting inflammation.
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